智通财经APP讯，复星医药(600196.SH)公告，2025年2月20日，公司控股子公司复星健康与上海卓尔荟及其另外三方股东(即星双健投资、复星健控和卓也健康，下同)签订《增资协议》，复星健康拟出资人民币3000万元认缴上海卓尔荟等值新增注册资本，其他股东均放弃优先认购权。本次增资适用的标的公司投前估值为人民币1.02亿元，系基于《资产评估报告》所载截至2024年10月31日标的公司的股东全部权益价值的评估值，经相关各方协商确定。
据悉，上海卓尔荟系一家为中高端人士提供一站式健康服务的营利性医疗机构，主要通过引进国内外优质医疗资源，提供体检、全科、专科门诊等医疗服务。本次增资款项将主要用于上海卓尔荟的日常运营以及学科、品牌及营销体系建设等。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.